Early Phase 1 Thyroid Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older who are willing and able to sign a written consent form
• People who have a solid tumour cancer that has spread or cannot be surgically removed, has tested positive for a protein called CD44v6, and has continued to grow or spread within the last 8 weeks despite standard treatments — with eligible cancer types including certain thyroid cancers (anaplastic, poorly differentiated, or radioiodine-refractory differentiated), head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), vulvar squamous cell cancer, or cervical squamous cell cancer
• People with thyroid cancer whose tumour carries a specific gene change (BRAFv600E) who have already received BRAF/MEK inhibitor treatment, or whose tumour does not have this gene change and have received at least one appropriate prior treatment (confirm specific treatment history requirements with trial site)
• People with head and neck squamous cell cancer who have received at least one prior combination chemotherapy regimen together with appropriate additional treatments based on their tumour's test results (confirm specific treatment history with trial site)
• People with non-small cell lung cancer who have received at least two prior treatment regimens, including an immunotherapy checkpoint inhibitor and a platinum-based chemotherapy
• People with vulvar squamous cell cancer who have completed both a first-line and a second-line treatment regimen as specified (confirm specific treatment history with trial site)
• People with cervical squamous cell cancer who have completed at least one line of standard treatment including platinum and paclitaxel-based therapy (confirm specific treatment history with trial site)
• People who have measurable disease that can be tracked using standard imaging assessment criteria
• People with a general health and activity level rated as 0 or 1 on a standard performance scale (meaning largely able to carry out normal daily activities with at most mild limitations)
• People whose doctor estimates they have a life expectancy of at least three months
• People whose blood counts, kidney function, liver function, and heart function all meet the required levels within eight days before starting treatment (confirm specific values with trial site)
• Women who could become pregnant must agree to use highly effective contraception during the study and for six months after the last dose, and must have a negative pregnancy test before each treatment infusion
• Men must agree to use barrier contraception (condoms) or completely avoid heterosexual intercourse during the study and for four months after the last dose

Who may not be able to join:

• People who have brain metastases (cancer spread to the brain) that are causing symptoms, have not been previously treated, or currently require steroid medications to manage them
• People who have been diagnosed with another cancer within the past five years, unless it was a completely treated skin cancer (basal or squamous cell) or cervical carcinoma in situ
• People who have received chemotherapy, targeted therapy, or radiotherapy within the four weeks before enrolling in the study
• People who still have significant side effects (rated above grade 1) from previous cancer treatments that have not resolved
• People who are pregnant or breastfeeding
• People with uncontrolled high blood pressure, or uncontrolled heart, liver, or kidney disease, or other serious medical or psychiatric conditions
• People with severe skin diseases that require systemic anti-inflammatory treatment, such as plaque psoriasis, Stevens-Johnson syndrome, or dermatomyositis
• People with a known history of HIV infection, active hepatitis B, active hepatitis C, or active tuberculosis

Important: Always verify eligibility with the trial site directly before applying.